The Community Practice Research Core, formerly the Community Practice Core, enables Dana-Farber/Harvard Cancer Center researchers to conduct cancer-related projects in real-world community settings. The Core provides easy access to a racially diverse population of over 11,000,000 patients within the local and national community-based clinical practices of Harvard Vanguard Medical Associates (HVMA)/Atrius Health, Harvard Pilgrim Health Care and HMO Cancer Research Network. Harvard Vanguard Medical Associates is a non-profit, multi-specialty medical group practice providing care to more than 480,000 adult and pediatric patients at over 21 offices across eastern Massachusetts. It is one of five medical groups that comprise Atrius Health. All Atrius groups share a single electronic medical record system (EPIC?), easing researchers'access to its 600,000 patients. Harvard Pilgrim Health Care is a non-profit health plan that provides medical insurance to more than 1,000,000 members in Massachusetts, New Hampshire and Maine. Cancer Research Network is an NCI-funded consortium of 14 integrated healthcare systems, representing 11,000,000 enrollees across the United States. This facility has been continuously funded by the CCSG since 2000. Director: Larissa Nekhlyudov, MD, MPH(HMS) Category: 3.01, 3.03 and 3.06 (Population Research) Management: Cancer Center managed.
The Core conducts research on cancer prevention, detection, treatment, long-term care, surveillance and survivorship. The populations that this core accesses are ideal for studies that involve basic, clinical and population sciences that address issues impacting diverse communities;need large samples of patients and/or providers;examine preventive strategies;include rare cancers;investigate the dissemination of proven technologies and interventions;and focus on cancer prevention.
|McBrayer, Samuel K; Mayers, Jared R; DiNatale, Gabriel J et al. (2018) Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell 175:101-116.e25|
|Stopsack, Konrad H; Gonzalez-Feliciano, Amparo G; Peisch, Samuel F et al. (2018) A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status. Cancer Epidemiol Biomarkers Prev 27:1231-1233|
|Kamareddine, Layla; Wong, Adam C N; Vanhove, Audrey S et al. (2018) Activation of Vibrio cholerae quorum sensing promotes survival of an arthropod host. Nat Microbiol 3:243-252|
|Schilit, Samantha L P; Morton, Cynthia C (2018) 3C-PCR: a novel proximity ligation-based approach to phase chromosomal rearrangement breakpoints with distal allelic variants. Hum Genet 137:55-62|
|Sievers, Quinlan L; Gasser, Jessica A; Cowley, Glenn S et al. (2018) Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity. Blood 132:1293-1303|
|Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296|
|Yao, Lina; Seaton, Sarah Craven; Ndousse-Fetter, Sula et al. (2018) A selective gut bacterial bile salt hydrolase alters host metabolism. Elife 7:|
|Jalbut, Marla M; Brunner, Andrew M; Amrein, Philip C et al. (2018) Early infectious complications among patients treated with induction compared to hypomethylating therapy for acute myeloid leukemia. Leuk Lymphoma 59:988-991|
|Tapela, Neo M; Peluso, Michael J; Kohler, Racquel E et al. (2018) A Step Toward Timely Referral and Early Diagnosis of Cancer: Implementation and Impact on Knowledge of a Primary Care-Based Training Program in Botswana. Front Oncol 8:187|
|Roemer, Margaretha G M; Redd, Robert A; Cader, Fathima Zumla et al. (2018) Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J Clin Oncol 36:942-950|
Showing the most recent 10 out of 411 publications